Appointments at Abeona
US gene therapy company Abeona Therapeutics (Nasdaq: ABEO) has appointed Victor Paulus as senior vice president, regulatory affairs.
The company also announced the appointment of Jodie Gillon as VP of patient advocacy and clinical affairs. Both Dr Paulus and Ms Gillon are reporting to chief executive Dr João Siffert.
Dr Paulus has over 30 years of experience in the pharmaceutical industry, including over 20 years specializing in regulatory affairs. Prior to joining Abeona, he served as VP and global head of regulatory affairs at the clinical-stage immunotherapy company Hookipa Pharma. Previously, Dr Paulus was global head of regulatory affairs for Advanced Accelerator Applications, a Novartis (NOVN: VX) company, where he secured orphan designations and product approvals for Gallium Ga68 dotatate and Lutetium Lu177 dotatate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze